Not all corners of the market are moving in the same direction this year; 2025 has already delivered a few surprises for ...

Shares of Viking Therapeutics slid despite what analysts at brokerage Leerink Partners called "rapid" enrollment for the drug developer's widely anticipated obesity drug trial. Rival makers of ...